How to Select VA Patients for IV Ketamine for Depression
How should clinicians identify which patients with depression are reasonable candidates for repeated intravenous ketamine treatment in routine care?
Patients considered for intravenous ketamine in routine VA care typically had severe, highly treatment-resistant depressive illness with substantial psychiatric comorbidity and prior use of other treatments. This guide helps clinicians frame candidate selection using the actual clinical profile of patients who received ketamine in Clinical Outcomes of Intravenous Ketamine Treatment for Depression in the VA Health System.
-
Confirm depressive illness as the treatment target
In this cohort, nearly all patients had major depressive disorder as the clinical target, with 98% carrying a past-year diagnosis of major depressive disorder and a small minority having another depressive disorder. Start by confirming that depression is the symptom domain driving treatment need rather than a nonpsychiatric indication for ketamine.
-
Establish that depression is highly treatment resistant
Patients who received intravenous ketamine in this study had extensive prior treatment exposure. Among those prescribed an antidepressant, they had a mean of 2.1 different antidepressant trials in the past year and 6.1 different antidepressant trials across the past 20 years, supporting use in patients who have already failed multiple oral antidepressant medications.
-
Review prior use of other intensive depression treatments
This VA sample had frequent use of higher-intensity psychiatric care before ketamine. In the prior 12 months, 22% had inpatient psychiatric treatment, 13% had received repetitive transcranial magnetic stimulation, and 18% had received electroconvulsive therapy, so review whether less costly or more accessible options have already been used or not benefitted the patient.
-
Assess baseline symptom severity and clinical burden
Baseline depression severity was substantial, with a mean PHQ-9 score of 18.6 at first infusion, in the moderately severe range. Patients also had heavy recent mental health service use, with a mean of 39 mental health visits in the prior year, indicating that ketamine was generally used in persistently symptomatic patients with high clinical burden.
-
Do not exclude solely on common psychiatric comorbidity
Comorbidity was common in the treated cohort, including 70% with posttraumatic stress disorder, 50% with other anxiety disorders, 27% with alcohol use disorders, and 27% with other substance use disorders. In bivariate analyses, demographic and diagnostic characteristics were not associated with 6-week PHQ-9 change, so common comorbid diagnoses alone did not distinguish who improved.
-
Set realistic expectations before starting treatment
Use the study's observed outcomes to frame expectations. At 6 weeks, 47% achieved a minimally clinically important difference defined as a 5-point PHQ-9 decrease, 26% achieved response defined as a 50% reduction, and 15% reached remission defined as PHQ-9 of 5 or less.
Clinical Considerations
- This study was observational and describes who received intravenous ketamine in VA routine care rather than a validated referral algorithm.
- The cohort was drawn from VA settings with highly treatment-resistant illness and substantial psychiatric comorbidity, so findings may not generalize to other health systems or earlier-line treatment use.
- The study did not include a direct safety assessment, so selection decisions cannot be based on adverse-event risk stratification from these data.
- Medical record diagnoses were used rather than structured diagnostic interviews, which may limit diagnostic precision.
Bottom Line
In routine VA practice, intravenous ketamine was primarily used for patients with major depressive disorder who had severe symptoms and multiple prior treatment failures, and common comorbidities such as posttraumatic stress disorder did not identify poorer 6-week outcomes.
